摘要
Pseudomonas aeruginosa is an opportunistic Gram-negative bacterium, responsible for nosocomial infections, with a complex arsenal of pathogenicity. The aim of this study was to simultaneously characterize the potential for resistance, virulence and biofilm formation in clinical strains. A total of 104 clinical P. aeruginosa strains (blood (26), stools (26), pus (26) and urine (26) were the subject of this study. The Mueller-Hinton diffusion method, agglutination test and combined disk diffusion test respectively made it possible to phenotypically determine the resistance profile, serogroups and metallo-β-lactamase production. Virulence, resistance and biofilm formation supports were detected by PCR. P. aeruginosa strains were resistant to aztreonam (76.4%), ticarcillin (62.4%), piperacillin (32.4%), imipenem (17.1%), cefepime (14%) and Ceftazidime (8.3%). The serogroups O11 (22.1%), O7 (18.3%), O16 (16.3%), and O9 (14.4%) were mainly determined in clinical strains. The total prevalence of metallo-β lactamase genes was 12.5% (blaIMP) and 11.5% (blaVIM). In descending order, the virulence genes exoS (55.8%), plcH (48.1%), LasB (47.1%), pilB (42.3%) and algD (41.3%) were detected (p pelA (28.8%) and pslA (23.1%). In conclusion, this study highlights the significant resistance, virulence, and biofilm-forming capabilities of clinical Pseudomonas aeruginosa strains. By profiling 104 strains, we found high resistance rates to multiple antibiotics, with notable serogroups and a considerable prevalence of metallo-β-lactamase genes, which pose a challenge for treatment. Additionally, key virulence genes and biofilm-associated genes were prevalent, underscoring the pathogenic potential of these strains. These findings underscore the importance of characterizing pathogenicity factors as a valuable strategy for monitoring and managing P. aeruginosa infections, especially in healthcare settings where such infections are common and difficult to treat.
Pseudomonas aeruginosa is an opportunistic Gram-negative bacterium, responsible for nosocomial infections, with a complex arsenal of pathogenicity. The aim of this study was to simultaneously characterize the potential for resistance, virulence and biofilm formation in clinical strains. A total of 104 clinical P. aeruginosa strains (blood (26), stools (26), pus (26) and urine (26) were the subject of this study. The Mueller-Hinton diffusion method, agglutination test and combined disk diffusion test respectively made it possible to phenotypically determine the resistance profile, serogroups and metallo-β-lactamase production. Virulence, resistance and biofilm formation supports were detected by PCR. P. aeruginosa strains were resistant to aztreonam (76.4%), ticarcillin (62.4%), piperacillin (32.4%), imipenem (17.1%), cefepime (14%) and Ceftazidime (8.3%). The serogroups O11 (22.1%), O7 (18.3%), O16 (16.3%), and O9 (14.4%) were mainly determined in clinical strains. The total prevalence of metallo-β lactamase genes was 12.5% (blaIMP) and 11.5% (blaVIM). In descending order, the virulence genes exoS (55.8%), plcH (48.1%), LasB (47.1%), pilB (42.3%) and algD (41.3%) were detected (p pelA (28.8%) and pslA (23.1%). In conclusion, this study highlights the significant resistance, virulence, and biofilm-forming capabilities of clinical Pseudomonas aeruginosa strains. By profiling 104 strains, we found high resistance rates to multiple antibiotics, with notable serogroups and a considerable prevalence of metallo-β-lactamase genes, which pose a challenge for treatment. Additionally, key virulence genes and biofilm-associated genes were prevalent, underscoring the pathogenic potential of these strains. These findings underscore the importance of characterizing pathogenicity factors as a valuable strategy for monitoring and managing P. aeruginosa infections, especially in healthcare settings where such infections are common and difficult to treat.
作者
Adjaratou Traore
Comoé Koffi Donatien Benie
Abdoulaye Diarrassouba
Wako-Tianwa Alice Tuo
Oby Zéphirin Wayoro
Adjéhi Dadié
Nathalie Guessennd
Mireille Dosso
Adjaratou Traore;Comoé Koffi Donatien Benie;Abdoulaye Diarrassouba;Wako-Tianwa Alice Tuo;Oby Zéphirin Wayoro;Adjéhi Dadié;Nathalie Guessennd;Mireille Dosso(Department of Medical Sciences, University of Alassane Ouattara, Bouak, Cte dIvoire;Bacteriology-Virology Laboratory, University Hospital Center (UHC) of Bouak, Bouak, Cte dIvoire;Laboratory of Biotechnology, Agriculture and Valorization of Biological Resources, Department of Biosciences, University of Flix Houphout Boigny, Abidjan, Cte dIvoire;Department of Bacteriology and Virology, Institute Pasteur of Cte dIvoire (IPCI), Abidjan, Cte dIvoire)
